PE20120647A1 - Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular - Google Patents
Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascularInfo
- Publication number
- PE20120647A1 PE20120647A1 PE2011001641A PE2011001641A PE20120647A1 PE 20120647 A1 PE20120647 A1 PE 20120647A1 PE 2011001641 A PE2011001641 A PE 2011001641A PE 2011001641 A PE2011001641 A PE 2011001641A PE 20120647 A1 PE20120647 A1 PE 20120647A1
- Authority
- PE
- Peru
- Prior art keywords
- prevention
- compositions
- treatment
- methods
- cardiovascular disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) AGENTE REDUCTOR DE COLESTEROL TAL COMO SIMVASTATINA ENTRE 5-140mg; B) UN INHIBIDOR DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA TAL COMO ENALAPRIL DE 1-80 mg; C) UN ANTIAGREGANTE PLAQUETARIO TAL COMO ACIDO ACETILSALICILICO DE 20-50 mg. DICHA COMPOSICION FARMACEUTICA ES DE ADMINISTRACION ORAL EN FORMA DE CAPSULA, TABLETA, POLVO DISPERSABLE EN AGUA O BEBIDAS Y ES UTIL EN LA PREVENCION DE ENFERMEDADES CARDIOVASULARES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16011009P | 2009-03-13 | 2009-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120647A1 true PE20120647A1 (es) | 2012-05-31 |
Family
ID=42727850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001641A PE20120647A1 (es) | 2009-03-13 | 2010-03-10 | Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100234442A1 (es) |
EP (1) | EP2405747A4 (es) |
CA (1) | CA2755543A1 (es) |
CL (1) | CL2011002265A1 (es) |
CO (1) | CO6420389A2 (es) |
MX (1) | MX357919B (es) |
PE (1) | PE20120647A1 (es) |
WO (1) | WO2010103384A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012388440B2 (en) * | 2012-08-27 | 2017-08-31 | Evonik Operations Gmbh | Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
WO2014178891A1 (en) | 2013-04-30 | 2014-11-06 | Otitopic Inc. | Dry powder formulations and methods of use |
EP3107548B8 (en) | 2014-02-20 | 2022-07-20 | Otitopic Inc. | Dry powder formulations for inhalation |
KR20230040375A (ko) | 2017-09-22 | 2023-03-22 | 오티토픽 인코퍼레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
JOP20210280A1 (ar) * | 2019-04-17 | 2023-01-30 | Cardiopharma Inc | توليفة ذات جرعة ثابتة مضادة لارتفاع ضغط الدم ومخفضة للكوليسترول وطريقة لتصنيعها |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
US4444762A (en) * | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
US4570630A (en) * | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
FR2585563B1 (fr) * | 1985-07-30 | 1993-11-12 | Glaxo Group Ltd | Dispositif pour administrer des medicaments a des patients |
US5271946A (en) * | 1988-04-20 | 1993-12-21 | Asta Pharma Aktiengesellschaft | Controlled release azelastine-containing pharmaceutical compositions |
NZ234143A (en) * | 1989-06-28 | 1991-10-25 | Mcneil Ppc Inc | Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents |
US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
US5140012A (en) * | 1990-05-31 | 1992-08-18 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing pravastatin |
US5622271A (en) * | 1995-09-19 | 1997-04-22 | Innovative Premiums Inc. | Wall hangable device |
DE19536902A1 (de) * | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
DE19617487A1 (de) * | 1996-05-02 | 1997-11-06 | Merck Patent Gmbh | Geschmacksverbesserung von Arzneimittelwirkstoffen |
US6071489A (en) * | 1996-12-05 | 2000-06-06 | Samsung Display Device Co., Ltd. | Methods of preparing cathode active materials for lithium secondary battery |
DE19814256A1 (de) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Feste, schnellzerfallende Cetirizin-Formulierungen |
US6260549B1 (en) * | 1998-06-18 | 2001-07-17 | Clavius Devices, Inc. | Breath-activated metered-dose inhaler |
US6596298B2 (en) * | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
US6615826B1 (en) * | 1999-02-26 | 2003-09-09 | 3M Innovative Properties Company | Slow spray metered dose inhaler |
GB2361185A (en) * | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
US6620438B2 (en) * | 2001-03-08 | 2003-09-16 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists |
US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
BRPI0412557A (pt) * | 2003-07-28 | 2006-09-19 | Reddys Lab Inc Dr | forma de dosagem farmacêutica de eventos cardiovasculares |
SE0303571D0 (sv) * | 2003-12-03 | 2003-12-22 | Microdrug Ag | Medical product for moisture-sensitive medicaments |
SE0303569L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | DPI för avlämning av fuktkänsliga medikament |
WO2009010810A2 (en) * | 2006-08-07 | 2009-01-22 | Wockhardt Limited | Cardiovascular combinations comprising ace and hmg-co-a inhibitors |
-
2010
- 2010-03-10 MX MX2011009587A patent/MX357919B/es active IP Right Grant
- 2010-03-10 PE PE2011001641A patent/PE20120647A1/es not_active Application Discontinuation
- 2010-03-10 WO PCT/IB2010/000506 patent/WO2010103384A1/en active Application Filing
- 2010-03-10 CA CA2755543A patent/CA2755543A1/en not_active Abandoned
- 2010-03-10 EP EP10750431A patent/EP2405747A4/en not_active Withdrawn
- 2010-03-12 US US12/723,252 patent/US20100234442A1/en not_active Abandoned
-
2011
- 2011-09-13 CL CL2011002265A patent/CL2011002265A1/es unknown
- 2011-09-21 CO CO11123616A patent/CO6420389A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2405747A4 (en) | 2013-01-16 |
WO2010103384A1 (en) | 2010-09-16 |
CO6420389A2 (es) | 2012-04-16 |
US20100234442A1 (en) | 2010-09-16 |
MX2011009587A (es) | 2011-10-13 |
EP2405747A1 (en) | 2012-01-18 |
CL2011002265A1 (es) | 2012-07-06 |
MX357919B (es) | 2018-07-25 |
CA2755543A1 (en) | 2010-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120647A1 (es) | Composiciones y metodos para el tratamiento y prevencion de la enfermedad cardiovascular | |
PH12016500216B1 (en) | Stable pharmaceutical composition and methods of using same | |
MX2012005744A (es) | Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. | |
UA106634C2 (uk) | Тверда фармацевтична дозована форма | |
PE20130574A1 (es) | Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
WO2008113066A3 (en) | Ubiquinol and alpha lipoic compositions | |
BR112013006597A2 (pt) | tablete para desintegração oral em múltiplas camadas, e a fabricação do mesmo | |
NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
GEP20156281B (en) | Orally administered corticosteroid compositions | |
MX2012003082A (es) | Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol. | |
MX2012003555A (es) | Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma. | |
IN2012DN06720A (es) | ||
EP2419138A4 (en) | GEL COMPOSITIONS FOR THE ADMINISTRATION OF PHARMACEUTICALLY ACTIVE COMPOUNDS | |
MX2011002065A (es) | Composicion farmaceutica a base de progesterona micronizada y sus usos. | |
PE20140255A1 (es) | Tableta dispersable en forma oral | |
UA99758C2 (ru) | Капсула для профилактики сердечно-сосудистых заболеваний | |
BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
CO6280474A2 (es) | Composicion farmaceutica para el tratamiento de la eyaculacion precoz | |
PE20110943A1 (es) | Formulacion oral solida de alisquireno | |
PE20071004A1 (es) | Composiciones farmaceuticas que comprenden la combinacion de ivabradina y perindropil | |
BR112012021445A2 (pt) | formulação farmacêutica ou neutracêutica. | |
GEP20146067B (en) | Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases | |
PE20110925A1 (es) | Formulacion galenica que comprende alisquireno y proceso para su preparacion mediante granulacion de extrusion fundida | |
HK1213783A1 (zh) | 布洛芬鈉片劑和製備包含布洛芬鈉的藥物組合物的方法 | |
GB201312583D0 (en) | Combination and composition for treating obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |